Australia, Aug. 18 -- CRISPR Therapeutics AG, owns the trademark (2635972) for 'CTX611' till March 16, 2036.
Status: registered:
Registered/protected
Classes: 5 [Cells for medical or clinical use in the field of gene therapy for the treatment of cardiovascular diseases and thromboembolic diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy], 42 [Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of gene therapy], 5 [All items in this class are claimed in the convention application.] and 42 [All items in this class are claimed in the convention application.]
Type of Mark: Word
Date of Acceptance: March 18
Registration Advertised: Aug. 17
For further details contact Griffith Hack.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2635972.
Disclaimer: Curated by HT Syndication.
